Experiences with
Tecartus

5 public posts

FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy - Applies to all approved therapies, but benefits still outweigh risks

The notice and investigation pertain to all currently approved BCMA- and CD19-targeted CAR T-cell products:[/i] [i] Axicabtagene ciloleucel (Yescarta)[/i] [i] Brexucabtagene autoleucel (Tecartus)[/i] [i] Ciltacabtagene autoleucel (Carvykti)[/i] [i] Lisocabtagene maraleucel (Breyanzi)[

The notice and investigation pertain to all currently approved BCMA- and CD19-targeted CAR T-cell products:[/i] [i] Axicabtagene ciloleucel (Yescarta)[/i] [i] Brexucabtagene autoleucel (Tecartus)[/i] [i] Ciltacabtagene autoleucel (Carvykti)[/i] [i] Lisocabtagene maraleucel (Breyanzi)[

1 year ago

COVID: Staying Safe As The Virus Evolves - LLS Podcast / CLL Society’s COVID-19 Update December 5th, 2022 / Dec 15 2022 end Antibody Study

These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®, Tecartus™

These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®, Tecartus™

Volunteerin CLL Support

2 years ago

COVID update: Who remains at higher risk? by LLS.org

These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®, Tecartus™

These include: • Bruton tyrosine kinase (BTK) inhibitors, such as Imbruvica® (ibrutinib), Brukinsa® (zanubrutinib) and Calquence® (acalabrutinib) • Anti-CD20 antibody treatments, such as Rituxan® (rituximab) and Gazyva® (obinutuzumab) • CD-19 targeting CAR T-therapy (Breyanzi®, Kymriah®, Tecartus™

Volunteerin CLL Support

2 years ago

Want to take advantage of all our features? Just log in!

or

LLS (Leukemia & Lymphoma Society) National Patient Registry Covid Vaccine guidelines

Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah, Tecartus or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.

Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah, Tecartus or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.

3 years ago

The LLS (USA) COVID-19 Vaccination Schedule - MODERATELY TO SEVERELY IMMUNOCOMPROMISED PATIENTS

Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah, Tecartus or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.

Patients who have had CAR T-therapy that targets the CD-19 protein (Breyanzi, Kymriah, Tecartus or Yescarta) should consider themselves immunosuppressed even if it has been more than two years from their treatment.

Volunteerin CLL Support

3 years ago